NCT04326257View on ClinicalTrials.gov

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 5, 2020

Primary Completion Date

August 12, 2023

Study Completion Date

August 12, 2024

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Nivolumab+Relatlimab

IV administration of both Nivolumab and Relatlimab

DRUG

Nivolumab+Ipilimumab

IV administration of both Nivolumab and Ipilimumab

Trial Locations (1)

15232

UPMC Hillman Cancer Center, Pittsburgh

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dan Zandberg

OTHER

NCT04326257 - Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | Biotech Hunter | Biotech Hunter